NCT07054684 Study of BHV-1400 in IgA Nephropathy
| NCT ID | NCT07054684 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Biohaven Therapeutics Ltd. |
| Condition | IgA Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-07-30 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2025-07-30 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility Criteria
Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07054684 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying IgA Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07054684 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07054684 currently recruiting?
Yes, NCT07054684 is actively recruiting participants. Contact the research team at clinicaltrials@biohavenpharma.com for enrollment information.
Where is the NCT07054684 trial being conducted?
This trial is being conducted at Farmington, United States, Miami Lakes, United States, Miami Lakes, United States, Orlando, United States and 11 additional locations.
Who is sponsoring the NCT07054684 clinical trial?
NCT07054684 is sponsored by Biohaven Therapeutics Ltd.. The trial plans to enroll 20 participants.